In at 1.15 and looking to add a few on some dips. At this point I'm only in for 200 shares.

This stock looks like most other pharm. plays and it will all depend on the studies and the FDA.

Here is the latest news:

Generex Biotechnology Announces North American Initiation of Generex Oral-lyn Phase III Diabetes Study
Monday April 7, 9:30 am ET
Patient Screening Underway in North America for the Company's Non-Injectable Insulin That is Absorbed in the Lining of the Mouth and Does Not Enter the Lungs


WORCESTER, Mass., April 7, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has initiated the Phase III protocol in North America for its proprietary buccally-absorbed oral insulin spray product, Generex Oral-lyn(tm), with the commencement of patient screening. The first screening took place in late March in Texas. Other clinical sites participating in the study located in the United States are in Texas, Maryland, Minnesota and California, and in Canada in the province of Alberta.
ADVERTISEMENT


The Phase III protocol, identified as GEN084-OL, calls for a six month trial which is expected to include 750 patients with Type-1 diabetes mellitus. The primary objective of the study is to compare the efficacy of Generex Oral-lyn and the RapidMist(tm) Diabetes Management System with that of standard regular injectable insulin therapy as measured by Hba1c in patients with Type-1 diabetes mellitus. Generex Oral-lyn is delivered into the mouth via the Company's proprietary RapidMist device. Unlike inhaled insulin products, buccally-absorbed Generex Oral-lyn does not enter the lungs.

``This clinical milestone represents a long history of research and development to optimization for Generex Oral-lyn which is now entering the final clinical stage in major jurisdictions,'' said George Markus, the Company's Vice President of Regulatory Affairs. ``Our product is designed to offer a safe and convenient alternative to prandial insulin injections which can improve treatment compliance and quality of life for patients with diabetes.''

Generex Oral-lyn is presently approved for commercial sale in India and Ecuador. The delivery of Generex Oral-lyn clinical supplies to global sites and centers, including Ukraine and Russia, is on-going with roll-out to other regions to follow.

About Generex

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. For more information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3831